Medicina · Nov 17, 2026

Cardiovascular Risk Assessment in Adults with Hypothyroidism: Interpreting General-Population Models in Clinical Context—A Narrative Review

By Georgescu LM, Igna AD, Tăut ECP et al.

Background and Objectives: Thyroid dysfunction can change cardiovascular risk factors, but whether thyroid measures improve individual risk prediction remains uncertain. We examined the interpretation of general-population cardiovascular models in adults with overt or subclinical hypothyroidism, distinguishing observed events from model-generated risk. Materials and Methods: A focused narrative PubMed search covered publications from 1 January 2014 to 6 September 2026, supplemented by reference-list screening and selected earlier landmark reports used as historical context. Evidence included prospective cohorts, individual-participant-data analyses, randomized trials, systematic reviews, risk-model papers, and clinical guidance. Evidence was interpreted by study design and cardiovascular endpoint; the Scale for the Assessment of Narrative Review Articles (SANRA) was consulted as a quality checklist without formal scoring. Results: A single 2014 Korean cohort found little improvement in discrimination when thyroid-stimulating hormone (TSH) was added to older cardiovascular models, despite a positive association between TSH and events in men. No study identified here prospectively tested the incremental value of TSH for SCORE2, SCORE2-Diabetes, QRISK3, or PREVENT in hypothyroid subgroups. Individual-participant-data analyses associate TSH ≥ 10 mIU/L with selected coronary and heart-failure outcomes, but this threshold has not been validated as a risk-model coefficient. In 100,250 adults, thyroid peroxidase antibody positivity was not independently associated with coronary or stroke outcomes. A hypothetical PREVENT-ASCVD calculation using published lipid changes in overt disease shifted 10-year modeled risk from 5.78% to 4.90% without demonstrating event reduction. Conclusions: A validated, population-appropriate cardiovascular model should be interpreted alongside documented thyroid phenotype and treatment timing, rather than numerically adjusted for thyroid status. Clinical decisions may require repeat measurements after thyroid stabilization, but existing guideline risk modifiers and established prevention indications should remain the basis for management.

doi.org/10.3390/medicina62112248Open accessBiomarkers

AgingResearch.News